Se connecter Inscription gratuite

Affimed N.V Transmettre P/E

Quel est le Transmettre P/E de Affimed N.V?

Le Transmettre P/E de Affimed N.V. est -5.91

Quelle est la définition de Transmettre P/E?



Le ratio prix à terme/bénéfice est le rapport entre le prix des actions d'une société et son bénéfice par action estimé pour les douze prochains mois.

The forward price to earnings ratio is similar to trailing price to earnings ratio but instead of net income uses estimated net earnings over next 12 months. Estimates are typically derived as the mean of those published by a select group of analysts with selection criteria varying. The forward price-to-earnings ratio is a powerful, but limited tool. It allows a quick snapshot of the company’s finances without getting down in the details of an accounting report.

Transmettre P/E des entreprises dans Health Care secteur sur NASDAQ par rapport à Affimed N.V

Que fait Affimed N.V?

affimed (symbol: afmd) is a nasdaq-listed clinical-stage biopharmaceutical company focused on discovering and developing targeted immuno-oncology therapies. immuno-oncology represents a highly promising approach to cancer treatment that seeks to harness the body’s own immune defenses to attack and destroy tumor cells. natural killer cells, or nk-cells, and t-cells belong to the most potent cells of the human defense arsenal. affimed’s proprietary, next-generation bispecific antibodies, termed tandabs®, are designed to bring nk-cells or t-cells into close proximity to cancer cells that ultimately triggers a signal cascade that leads to the destruction of cancer cells. due to their novel tetravalent tandem architecture, which provides for four binding domains, the tandabs bind to specific targets on immune and cancer cells with high affinity. in addition, tandabs exhibit kinetic properties allowing the administration as regular intravenous infusion and fine-tuning of dosing. affimed beli

Entreprises avec transmettre p/e similaire à Affimed N.V